5-HT$_{2C}$Rs Expressed by Pro-opiomelanocortin Neurons Regulate Insulin Sensitivity in Liver

Yong Xu$^{1,3,*}$, Eric D. Berglund$^{1,7}$, Jong-Woo Sohn$^1$, William L. Holland$^2$, Jen-Chieh Chuang$^1$, Makoto Fukuda$^1$, Jari Rossi$^1$, Kevin W. Williams$^1$, Juli E. Jones$^3$, Jeffrey M. Zigman$^1$, Bradford B. Lowell$^4$, Philipp E. Scherer$^2$, and Joel K. Elmquist$^1$

$^1$Division of Hypothalamic Research and Departments of Internal Medicine and Pharmacology UT Southwestern Medical Center, Dallas, TX 75390
$^2$Touchstone Diabetes Center, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390
$^3$Children’s Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030
$^4$Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215

Abstract

Mice lacking 5-HT 2C receptors (5-HT$_{2C}$Rs) displayed insulin resistance in the liver, a phenotype normalized by re-expression of 5-HT$_{2C}$Rs only in pro-opiomelanocortin (POMC) neurons. 5-HT$_{2C}$R deficiency also abolished anti-diabetic effects of mCPP (a 5-HT$_{2C}$R agonist) while such effects were restored in mice with 5-HT$_{2C}$Rs re-expressed in POMC neurons. Our findings demonstrated that 5-HT$_{2C}$Rs expressed by POMC neurons are physiologically relevant regulators of insulin sensitivity and glucose homeostasis in the liver.

5-hydroxytryptamine 2C receptors (5-HT$_{2C}$Rs) in the brain regulate energy balance and glucose homeostasis. A selective 5-HT$_{2C}$R agonist, metachlorophenylpiperazine (mCPP), ameliorates insulin resistance and glucose intolerance in mice with diet-induced obesity (DIO). However, mechanisms underlying these effects are unclear. Pro-opiomelanocortin (POMC) neurons in the hypothalamic arcuate nucleus (ARC) produce α-melanocyte-stimulating hormone (α-MSH), an agonist of melanocortin 4 receptors (MC4Rs). The central melanocortin system plays essential roles in the regulation of feeding and glucose homeostasis. POMC neurons express 5-HT$_{2C}$Rs and receive innervation from serotoninergic neurons. 5-HT drugs, including mCPP, activate POMC neurons.

Users may view, print, copy, download and text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

Correspondence should be addressed to J.K.E. Joel K. Elmquist UT Southwestern Medical Center 5323 Harry Hines Boulevard, Dallas, Texas 75390-9077 Joel.Elmquist@UTSouthwestern.edu.

*These authors contributed equally to this work.

Author Contribution YX conducted glucose/insulin experiments and wrote the manuscript; EDB performed clamp studies; JWS and KWW conducted electrophysiological recordings; JIC, MF and JR contributed to the islet studies; JEJ, JMZ and BBL generated mice; WHL, PES and BBL assisted in data interpretation; JKE supervised the project.
addition, 5-HT$_2$CR agonists stimulate POMC expression. Using mice with global 5-HT$_2$CR deficiency (2C null mice) and mice with 5-HT$_2$CRs expressed only in POMC neurons (2C/POMC mice), we have demonstrated that POMC neurons contribute to the ability of 5-HT$_2$CR agonists to suppress feeding. Here we sought to use the same mouse models to determine whether 5-HT$_2$CRs expressed by POMC neurons also mediate 5-HT$_2$CRs' effects on glycemic control.

As reported previously, 2C null mice do not express 5-HT$_2$CRs. In 2C/POMC mice, 5-HT$_2$CRs are re-expressed only in brain sites where POMC is expressed (the hypothalamus and brainstem). Further, using electrophysiological recordings, we found that mCPP depolarized 26% POMC neurons in WT mice (Fig. 1). This mCPP-induced depolarization was abolished in POMC neurons from 2C null mice, but restored in 2C/POMC mice (Fig. 1). Therefore, 5-HT$_2$CRs are selectively re-expressed in POMC neurons in 2C/POMC mice. It should be noted that POMC is also expressed by neurons in the nucleus of solitary tract (NTS). Thus we cannot rule out that the small number of POMC neurons in the NTS may contribute to the responses outlined below.

Since 2C null mice display late-onset obesity and hyperadiposity, phenotypes that may interfere with glucose homeostasis, all studies were performed in young mice with matched body weight and/or body adiposity (Supplemental Table 1). We first assessed the insulin sensitivity using insulin tolerance tests (ITTs). While intraperitoneal injections of insulin induced robust decreases in blood glucose in chow-fed wildtype (WT) mice, 2C null littermates were significantly resistant to insulin (Fig. 2a). Notably, insulin sensitivity in 2C/POMC mice was rescued to WT level (Fig. 2a), indicating that 5-HT$_2$CRs expressed by POMC neurons were sufficient to normalize insulin resistance resulting from global 5-HT$_2$CR deficiency. Despite insulin resistance, 2C null mice showed normal glucose clearance rate in glucose tolerance tests (GTTs) (Fig. 2b), and normal glucose levels at fed and fasted conditions (Fig. 2c). The basal insulin levels at fed condition were slightly but not significantly higher in 2C null mice than in WT and 2C/POMC littermates (Figure 2d).

Fasted insulin levels were comparable in these mice (Figure 2d). Similar phenotypes were observed in mice fed with high fat diet (HFD) (Supplemental Fig. 1a–d). Since 2C null mice had normal glucose clearance rate while being insulin resistant, islets in these mice may have undergone compensatory adaptations which allowed elevated insulin secretion in response to hyperglycemia. Supporting this hypothesis, we found that a glucose load (0.75g/kg, i.p.) induced a significantly elevated serum insulin level in 2C null mice than in WT mice, and this hyperinsulinemia was normalized in 2C/POMC mice (Fig. 2e).

Consistently, we found that in vitro glucose-stimulated insulin secretion was significantly potentiated in 2C null islets when compared to islets isolated from WT and 2C/POMC mice (Supplemental Figure 1e). We cannot rule out the possibility that the increased islet sensitivity to glucose challenge may be the direct outcome of 5-HT$_2$CR deficiency. However, it is more likely that this islet phenotype in 2C null mice is a secondary adaptation which occurs to compensate for insulin resistance.

We next performed the hyperinsulinemic-euglycemic clamp studies to assess mechanisms underlying the insulin resistance found in ITT studies. We found the glucose infusion rate (GIR) needed to maintain euglycemia was reduced in 2C null mice compared to WT.
littermates (Figure 2f). GIR in 2C/POMC mice was fully restored to WT levels (Fig. 2f). In addition, the basal hepatic glucose production (HGP) and glucose disposal were higher in 2C null versus WT mice (Fig. 2g–h). The expected insulin-mediated suppression of HGP and increase in glucose disposal were evident in WT mice (Fig. 2g–h). A comparable rise in insulin in 2C null mice during the clamp failed to fully suppress HGP whereas glucose disposal rates were comparable (Fig. 2g–h). Notably, insulin-mediated suppression of HGP was fully restored in 2C/POMC mice (Fig. 2g). Collectively, these results demonstrated that insulin resistance caused by global 5-HT2C R deficiency was due to impaired hepatic insulin action and re-expression of 5-HT2C Rs only in POMC neurons was sufficient to rescue this impairment. These findings support the model that 5-HT2C-R-melanocortin circuits regulate the liver to control peripheral insulin sensitivity and glucose balance.

To further investigate whether 5-HT2C Rs expressed by POMC neurons are sufficient to mediate effects of 5-HT drugs on glucose homeostasis, we tested the effects of mCPP on GTTs and ITTs in DIO mice. Pre-treatments with mCPP (1.5 mg/kg, i.p.) in WT DIO mice significantly improved glucose tolerance and insulin sensitivity (Fig. 2i–j). In contrast, mCPP failed to produce these anti-diabetic effects in 2C null mice (Fig. 2i–j). Remarkably, mCPP-induced improvement in the GTTs and ITTs were restored in 2C/POMC mice (Fig. 2i–j). Therefore, our results support the model that 5-HT2C Rs expressed by POMC neurons are sufficient to mediate the anti-diabetic effects of 5-HT2C-R agonists.

Activation of 5-HT2C Rs in POMC neurons has been shown to stimulate firing activity of these neurons (see reference 4 and Fig. 1). This presumably leads to increased release of neurotransmitters (e.g. α-MSH, glutamate, etc.), which may underlie the mechanisms by which 5-HT2C R regulates glucose homeostasis. In addition, 5-HT2C R agonists may also regulate production of neurotransmitters in POMC neurons. Supporting this notion, 5-HT2C R agonists stimulate POMC expression. Consistent with this observation, we found that 2C null mice had significantly lower POMC expression in the ARC compared to their WT littermates, a phenotype that was restored in 2C/POMC mice (Supplemental Figure 1f).

It is important to note that our results do not exclude the possibility that redundant 5-HT2C R populations may also mediate similar effects. For example, 5-HT2C Rs are found in other CNS regions implicated in the regulation of glucose homeostasis, including the paraventricular nucleus of the hypothalamus, the ventromedial hypothalamic nucleus, and other sites. These regions all receive serotonergic projections. The physiological relevance of 5-HT2C Rs in these sites is yet to be characterized. However, our unique mouse model will allow us to directly address the importance of 5-HT2C Rs in any site in which specific expression of Cre-recombinase can be directed. In conclusion, we have provided evidence that 5-HT2C Rs expressed by POMC neurons are physiologically important in regulating hepatic glucose production and insulin sensitivity. Moreover, this 5-HT2C-R-melanocortin circuit is sufficient to mediate the anti-diabetic effects of 5-HT2C-R agonists.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.
Acknowledgment

We thank UTSW Mouse Metabolic Phenotyping Core (PL1 DK081182 and UL1RR024923). This work was supported by YX (CIHR and K09DK085330), EDB (TL1DK081181), WLH (F32 DK083866-01), MF (AHA), JR (Sigrid Jusélius Foundation), KWW (K01 DK087780), JMZ (K08DK068069), BBL (PO1 DK56116), and JKE (R01DK53301, R01MH61583, and RL1DK081185).

References

1. Wade JM, et al. Synergistic impairment of glucose homeostasis in ob/ob mice lacking functional serotonin 2C receptors. Endocrinology. 2008; 149:955–961. [PubMed: 18039786]
2. Zhou L, et al. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab. 2007; 6:398–405. [PubMed: 17983585]
3. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci. 2005; 8:571–578. [PubMed: 15856065]
4. Heisler LK, et al. Activation of central melanocortin pathways by fenfluramine. Science. 2002; 297:609–611. [PubMed: 12142539]
5. Kiss J, Leranth C, Halasz B. Serotonergic endings on VIP-neurons in the suprachiasmatic nucleus and on ACTH-neurons in the arcuate nucleus of the rat hypothalamus. A combination of high resolution autoradiography and electron microscopic immunocytochemistry. Neurosci Lett. 1984; 44:119–124. [PubMed: 6324050]
6. Xu Y, et al. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron. 2008; 60:582–589. [PubMed: 19038216]
7. Fan W, et al. Cholecystokinin-mediated suppression of feeding involves the brainstem melanocortin system. Nat Neurosci. 2004; 7:335–336. [PubMed: 15034587]
8. Hoffman BJ, Mezey E. Distribution of serotonin 5-HT1C receptor mRNA in adult rat brain. FEBS Lett. 1989; 247:453–462. [PubMed: 2714444]
9. Steinbusch HW. Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience. 1981; 6:557–618. [PubMed: 7017455]
Figure 1.
mCPP-induced depolarization of POMC neurons is abolished in 2C null mice, but restored in 2C/POMC mice. (a) Whole-cell capacitance and resting membrane potential of POMC neurons. The numbers of cells recorded are indicated in the parentheses. (b) mCPP-induced changes in membrane potential (ΔmCPP) from all recorded POMC neurons (left bars) and depolarized POMC neurons only (right bars). *, P<0.05. (c) The percentage of POMC neurons that depolarized in response to mCPP. (d) Representative membrane potential traces. Horizontal bars indicate the period of mCPP treatment. Dotted lines indicate the resting membrane potential. Scale bars indicate 10 mV (vertical) and 30 s (horizontal). All data are presented as mean ± s.e.m.
Figure 2.
Re-expression of 5-HT$_{2C}$Rs in POMC neurons rescues insulin resistance. (a) Insulin tolerance tests in chow-fed mice (insulin 1 U/kg). N=8 or 9/genotype. * or ***, P<0.05 or P<0.001 between 2C null vs WT mice; # or ###, P<0.05 or P<0.001 between 2C null vs 2C/POMC mice. (b) Glucose tolerance tests in chow-fed mice (glucose 1 g/kg). N=5–12/genotype. (c) Serum glucose at fed or fasted conditions in chow-fed mice. N=6–12/genotype. (d) Serum insulin at fed or fasted conditions in chow-fed mice. N=12–23/genotype. (e) Serum insulin at 30 min after HFD-fed mice received a glucose bolus injection (0.75 g/kg). N=6–14/genotype. * or **, P<0.05 or P<0.01. (f) Glucose infusion rate during a hyperinsulinemic-euglycemic clamp in chow-fed mice. N=7–9/genotype. *, ** or ###, P<0.05, P<0.01 or P<0.001 between 2C null vs WT mice; #, ## or ###, P<0.05, P<0.01 or P<0.001 between 2C null vs 2C/POMC mice. (g) Hepatic glucose production at basal (pre-clamp) or hyperinsulinemic clamp conditions. N=7–9/genotype. * or ***, P<0.05 or P<0.001. (h) Glucose disposal rate at basal (pre-clamp) or hyperinsulinemic clamp conditions. N=7–9/genotype. *, P<0.05. (i) Intraperitoneal injections of saline or mCPP (1.5 mg/kg), followed by GTT (0.75 g/kg) in WT, 2C null and 2C/POM mice. (j) Intraperitoneal injections of saline or mCPP (1.5 mg/kg), followed by ITT (1.5 U/kg) in WT, 2C null and 2C/POM mice. N=8–9/group. *, ** or ***, P<0.05, P<0.01 or P<0.001 between saline vs mCPP. All data are presented as mean ± s.e.m. Care of all animals and procedures were approved by UTSW Institutional Animal Care and Use Committees.